106 related articles for article (PubMed ID: 25384383)
1. AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance.
Li CF; Fang FM; Lan J; Wang JW; Kung HJ; Chen LT; Chen TJ; Li SH; Wang YH; Tai HC; Yu SC; Huang HY
Clin Cancer Res; 2014 Dec; 20(23):6141-52. PubMed ID: 25384383
[TBL] [Abstract][Full Text] [Related]
2. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Li CF; Chen LT; Lan J; Chou FF; Lin CY; Chen YY; Chen TJ; Li SH; Yu SC; Fang FM; Tai HC; Huang HY
Oncotarget; 2014 Nov; 5(22):11588-603. PubMed ID: 25473890
[TBL] [Abstract][Full Text] [Related]
3. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Li CF; Wang JM; Kang HY; Huang CK; Wang JW; Fang FM; Wang YH; Wu WR; Li SH; Yu SC; Lee JC; Lan J; Shiue YL; Wu LC; Huang HY
Clin Cancer Res; 2012 Mar; 18(6):1598-610. PubMed ID: 22322669
[TBL] [Abstract][Full Text] [Related]
4. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
[TBL] [Abstract][Full Text] [Related]
5. Recurrent amplification at 7q21.2 Targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator.
Tsai JW; Li CF; Kao YC; Wang JW; Fang FM; Wang YH; Wu WR; Wu LC; Hsing CH; Li SH; Yu SC; Lan J; Huang HY
Ann Surg Oncol; 2012 Aug; 19(8):2716-25. PubMed ID: 22476749
[TBL] [Abstract][Full Text] [Related]
6. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Huang HY; Kang HY; Li CF; Eng HL; Chou SC; Lin CN; Hsiung CY
Clin Cancer Res; 2006 Jan; 12(2):487-98. PubMed ID: 16428491
[TBL] [Abstract][Full Text] [Related]
7. Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.
Wu LC; Chen LT; Tsai YJ; Lin CM; Lin CY; Tian YF; Sheu MJ; Uen YH; Shiue YL; Wang YH; Yang SJ; Wu WR; Li SH; Iwamuro M; Kobayasshi N; Huang HY; Li CF
J Clin Pathol; 2012 Apr; 65(4):309-14. PubMed ID: 22267983
[TBL] [Abstract][Full Text] [Related]
8. Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.
Li CF; Fang FM; Kung HJ; Chen LT; Wang JW; Tsai JW; Yu SC; Wang YH; Li SH; Huang HY
Oncotarget; 2014 Nov; 5(22):11428-41. PubMed ID: 25426549
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis.
Lee JC; Li CF; Fang FM; Wang JW; Jeng YM; Yu SC; Lin YT; Wu JM; Tsai JW; Li SH; Huang HY
Mod Pathol; 2010 Oct; 23(10):1379-92. PubMed ID: 20639860
[TBL] [Abstract][Full Text] [Related]
10. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
11. Clinical aggressiveness of myxofibrosarcomas associates with down-regulation of p12CDK2AP1: prognostic implication of a putative tumor suppressor that induces cell cycle arrest and apoptosis via mitochondrial pathway.
Li CF; Huang HY; Wu WR; Liang SS; Chen YL; Chen LR; Peng YT; Lee HC; Shiue YL
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S711-20. PubMed ID: 24889487
[TBL] [Abstract][Full Text] [Related]
12. RSF1 requires CEBP/β and hSNF2H to promote IL-1β-mediated angiogenesis: the clinical and therapeutic relevance of RSF1 overexpression and amplification in myxofibrosarcomas.
Li CF; Chan TC; Wang CI; Fang FM; Lin PC; Yu SC; Huang HY
Angiogenesis; 2021 Aug; 24(3):533-548. PubMed ID: 33496909
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Lin A; Weiser MR; Klimstra DS; Paty PB; Tang LH; Al-Ahmadie H; Hoo Park S; Guillem JG; Temple L; Wong WD; Gerald WL; Shia J
Hum Pathol; 2007 Jun; 38(6):850-6. PubMed ID: 17442371
[TBL] [Abstract][Full Text] [Related]
14. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
15. AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
He HL; Lee YE; Chang MT; Shiue YL; Chang SL; Chen TJ; Chiu CT
Int J Med Sci; 2018; 15(6):638-644. PubMed ID: 29725255
[No Abstract] [Full Text] [Related]
16. AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Lee YE; He HL; Lee SW; Chen TJ; Chang KY; Hsing CH; Li CF
Tumour Biol; 2014 Aug; 35(8):7983-91. PubMed ID: 24833092
[TBL] [Abstract][Full Text] [Related]
17. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
18. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
19. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
Shi XY; Bhagwandeen B; Leong AS
Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):447-52. PubMed ID: 18665038
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
